NCT05188053View on ClinicalTrials.gov

Periarticular Bupivacaine + Meloxicam ER Solution Versus Standard Practice During Total Knee Arthroplasty

PHASE4CompletedINTERVENTIONAL
Enrollment

209

Participants

Timeline

Start Date

March 11, 2022

Primary Completion Date

April 18, 2024

Study Completion Date

April 18, 2024

Conditions
Total Knee Arthroplasty
Interventions
DRUG

HTX-011

Single dose administration periarticular 400mg bupivacaine and 12mg meloxicam extended release solution

DRUG

ropivacaine , epinephrine , ketorolac diluted in sodium chloride

Single dose administration in 100cc of standard formulation, there is 225mg of ropivacaine 5mg/mL, 0.6mg epinephrine 1mg/mL, 30mg ketorolac 30mg/mL diluted in sodium chloride

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT05188053 - Periarticular Bupivacaine + Meloxicam ER Solution Versus Standard Practice During Total Knee Arthroplasty | Biotech Hunter | Biotech Hunter